



Pharmaceuticals Limited

Reg. Off : Plot No. 22 & 23
SVCIE, Bachupally
Qutabullapur Mandal
Hyderabad-500090. INDIA
Phone: +91-40-32485500
email: invinex@yahoo.com

INWINEX PHARMACEUTICALS LTD						
REGD. OFFICE: Plot No.22 & 23, SVCIE, Bachupally, Qutabullapur (M), Hyderabad-500 090						
UNAUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 30th SEPTEMBER, 2011						
(Rs. in Lacs)						
Sl. No.	Particulars	Quarter Ended 30.09.2011	Corresponding Quarter Ended 30.09.2010	Year to date Figures for 30.09.2011	Year to date Figures for 30.09.2010	Audited Figures Year Ended 31.03.2011
1	(a) Gross Sales/Income from Operations	22.96	10.40	57.11	12.93	47.72
	Less: Excise Duty	2.16	-	4.60	-	3.64
	Net Sales/Income from Operations	20.80	10.40	52.51	12.93	44.09
	(b) Other Operating Income	0.10	0.68	0.10	1.04	3.60
2	EXPENDITURE					
a.	(Increase)/Decrease in Stock-In-Trade	(3.60)	-	(1.75)	-	(7.16)
b.	Consumption of Raw Materials	12.50	0.85	24.22	4.23	26.24
c.	Employees Cost	16.11	4.13	24.92	11.45	25.65
d.	Depreciation	4.91	4.12	9.80	8.19	17.76
e.	Provision for Doubtful Debts, Loans & Advances and Deposits	-	-	-	-	43.98
f.	Other Expenditure	22.74	11.84	37.52	25.97	71.21
g.	Total	52.67	20.94	94.72	49.84	177.68
3	Profit from Operations before Other Income, Interest and Exceptional items (1-2)	(31.77)	(9.86)	(42.11)	(35.87)	(130.00)
4	Other Income	-	-	-	-	-
5	Profit before Interest and Exceptional Items (3+4)	(31.77)	(9.86)	(42.11)	(35.87)	(130.00)
6	Interest	0.02	0.01	0.05	0.02	0.04
7	Profit after interest but before Exceptional Items (5-6)	(31.79)	(9.87)	(42.16)	(35.89)	(130.04)
8	Exceptional Items (Loss on sale of Fixed Assets)	-	-	-	-	-
9	Profit/(Loss) before from Ordinary Activities before tax (7+8)	(31.79)	(9.87)	(42.16)	(35.89)	(130.04)
10	Tax expenses	-	-	-	-	-
11	Net Profit/(Loss) from Ordinary Activities after tax (9-10)	(31.79)	(9.87)	(42.16)	(35.89)	(130.04)
12	Extraordinary items (net of tax expenses Rs. Nil)	-	-	-	-	-
13	Net Profit/(Loss) for the period	(31.79)	(9.87)	(42.16)	(35.89)	(130.04)
14	Paid up Equity Share Capital (Face value of Rs.10)	450.00	450.00	450.00	450.00	450.00
15	Reserves & Surplus Excluding Revaluation Reserves as per Balance sheet of previous year					
16	Earnings per Share (EPS)					
a.	Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (Not Annualised)	(0.71)	(0.22)	(0.94)	(0.80)	(2.89)
b.	Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (Not Annualised)	(0.71)	(0.22)	(0.94)	0.80	(2.89)
17	Public Shareholding					
a)	Number of Equity Shares Rs.10/- each	1141326	1131856	1141326	1131856	1141326
b)	Percentage of Shareholding	25.36%	25.15%	25.36%	25.15%	25.36%
18	Promoters and Promoter Group Shareholding					
a.	Pledged/Encumbered					
	- Number of Shares	-	-	-	-	-
	- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter group)	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-
b.	Non-encumbered					
	- Number of Shares	3358714	3368184	3358714	3368184	3358714
	- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter group)	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the company)	74.64%	74.85%	74.64%	74.85%	74.64%

Notes:

- Figures have been regrouped, wherever necessary.
- The Company does not have more than one reportable segment. Accordingly, pursuant to Accounting Standard (AS-17) on Segment Reporting issued by the Institute of Chartered Accountants of India, segmental information is not required to be provided.
- Number of Investor complaints pending during the Quarter - Nil.
- The above results were reviewed by the Audit Committee and approved by the Board in its meeting held on the 15th November, 2011.

Place: Hyderabad
Date : 14.11.2011

By Order of the Board
For INWINEX PHARMACEUTICALS LIMITED

MANAGING DIRECTOR

